The content on this site is intended for healthcare professionals only
Dr Pedro Rocha speak to ecancer about results from the phase 1b DeLLphi-308 study evaluating subcutaneous tarlatamab in patients with previously treated extensive-stage small cell lung cancer.
He reports that the selected 15 mg subcutaneous dose achieved comparable drug exposure to the established intravenous regimen, while offering the potential for more convenient administration.
Dr Rocha explains that treatment was generally well tolerated, with cytokine release syndrome predominantly grade 1 and no grade 3 or higher events. This safety profile supported the elimination of mandatory post-dose monitoring during the study.
Preliminary efficacy was also observed, with an objective response rate of 30% at the selected 15 mg dose, supporting further evaluation of subcutaneous tarlatamab as a potentially more convenient treatment approach for SCLC.
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML
Epcoritamab plus rituximab and lenalidomide improves outcomes across follicular lymphoma subgroups
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma
Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
